Is correction for protein concentration appropriate for protein adduct dosimetry? Hypothesis and clues from an aflatoxin B1-exposed population

Cancer Science

Volumn 98, Issue 2, 2007, Pages 140-146

  Peng, Tao ^a,b   Li, Le Qun ^a   Peng, Min Hao ^a   Liu, Zhi Ming ^a   Liu, Tang Wei ^a   Yan, Lu Nan ^c   Shen, Han Ming ^d   Wang, LianWen ^b   Wang, Qiao ^b   Wang, Kai Bo ^e   Liang, Ren Xiang ^e   Wei, Zong Liang ^e   Ong, Choon Nam ^d   Santella, Regina M ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b Columbia University ^*  (United States)

^c SICHUAN UNIVERSITY   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e Fusui Cancer Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CARBONYL DERIVATIVE;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER MORTALITY; CARCINOGENESIS; CHINA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; HYPOTHESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; OXIDATIVE STRESS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AFLATOXIN B1; ALBUMINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHINA; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; OXIDATIVE STRESS; RISK FACTORS;

EID: 33845665281     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00380.x     Document Type: Article

References (53)

1. Goldman R, Shields PG. Food mutagens. J Nutr 2003; 133 (Suppl 3): S965-73.
2. Sheabar FZ, Groopman JD, Qian GS et al. Quantitative analysis of aflatoxin-albumin adducts. Carcinogenesis 1993; 14: 1203-8.
3. Skipper PL, Tannenbaum SR. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis 1990; 11: 507-18.
4. Sharma RA, Farmer PB. Biological relevance of adduct detection to the chemoprevention of cancer. Clin Cancer Res 2004; 10: 4901-12.
5. Jeffrey AM, Williams GM. Risk assessment of DNA-reactive carcinogens in food. Toxicol Appl Pharmacol 2005; 207 (Suppl 2): 628-35.
6. Groopman JD, Kensler TW. Role of metabolism and viruses in aflatoxin-induced liver cancer. Toxicol Appl Pharmacol 2005; 206: 131-7.
7. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 1996; 366: 23-44.
8. Kodama M, Inoue F, Akao M. Enzymatic and non-enzymatic formation of free radicals from aflatoxin B1. Free Radic Res Commun 1990; 10: 137-42.
9. Wild CP, Jiang YZ, Sabbioni G et al. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res 1990; 50: 245-51.
10. Droge W. Oxidative stress and aging. Adv Exp Med Biol 2003; 543: 191-200.
11. Dean RT, Fu S, Stocker R et al. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324: 1-18.
12. Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: Protein carbonyl content as a marker of damage. Free Radic Res 2000; 33 (Suppl): S99-108.
13. Wang JS, Qian GS, Zarba A et al. Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1996; 5: 253-61.
14. Gan LS, Skipper PL, Peng XC et al. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: Correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. Carcinogenesis 1988; 9: 1323-5.
15. Tao P, Zhi-Ming L, Tang-Wei L et al. Associated factors in modulating aflatoxin B1-albumin adduct level in three Chinese populations. Dig Dis Sci 2005; 50: 525-32.
16. Chen CJ, Wang LY, Lu SN et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24: 38-42.
17. Buss H, Chan TP, Sluis KB et al. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997; 23: 361-6.
18. Halliwell B. Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic Res 1996; 25: 57-74.
19. Willard RC, Joyce M. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res 1991; 20: 1-116.
20. Yousef MI, Salem MH, Kamel KI et al. Influence of ascorbic acid supplementation on the haematological and clinical biochemistry parameters of male rabbits exposed to aflatoxin B1. J Environ Sci Health B 2003; 38: 193-209.
21. Moundipa PF, Domngang FM. Effect of the leafy vegetable Solanum nigrum on the activities of some liver drug-metabolizing enzymes after aflatoxin B1 treatment in female rats. Br J Nutr 1991; 65: 81-91.
22. Guengerich FP, Arneson KO, Williams KM et al. Reaction of aflatoxin B 1 oxidation products with lysine. Chem Res Toxicol 2002; 15: 780-92.
23. Kensler TW, Qian GS, Chen JG et al. Translational strategies for cancer prevention in liver. Nat Rev Cancer 2003; 3: 321-9.
24. Coulombe RA Jr, Sharma RP. Clearance and excretion of intratracheally and orally administered aflatoxin B1 in the rat. Food Chem Toxicol 1985; 23: 827-30.
25. Wilson R, Ziprin R, Ragsdale S et al. Uptake and vascular transport of ingested aflatoxin. Toxicol Lett 1985; 29: 169-76.
26. Ewaskiewicz JI, Devlin TM, Ch'ih JJ. The in vivo disposition of aflatoxin B1 in rat liver. Biochem Biophys Res Commun 1991; 179: 1095-100.
27. Ch'ih JJ, Ewaskiewicz JI, Taggart P et al. Nuclear translocation of aflatoxin B1-protein complex. Biochem Biophys Res Commun 1993; 190: 186-91.
28. Sabbioni G, Skipper PL, Buchi G et al. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 1987; 8: 819-24.
29. 1 in rats by isotope dilution mass spectrometry. Chem Res Toxicol 2006; 19: 44-9.
30. Wild CP, Hasegawa R, Barraud L et al. Aflatoxin-albumin adducts: A basis for comparative carcinogenesis between animals and humans. Cancer Epidemiol Biomarkers Prev 1996; 5: 179-89.
31. Hu ML, Louie S, Cross CE et al. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993; 121: 257-62.
32. Rosenoer VM. Clinical aspects of albumin metablism. In: Rosenoer VM, Oratz M, Rothschild MA, eds. Albumin Structure, Function and Uses. Oxford, UK: Pergamon Press, 1977; 345-67.
33. Egner PA, Gange SJ, Dolan PM et al. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis 1995; 16: 1769-73.
34. Wild CP, Jansen LA, Cova L et.al. Molecular dosimetry of aflatoxin exposure: Contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ Health Perspect 1993; 99: 115-22.
35. Pantke U, Volk T, Schmutzler M et al. Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic Biol Med 1999; 27: 1080-6.
36. Abu-Zidan FM, Winterbourn CC, Bonham MJ et al. Small bowel ischaemia-reperfusion increases plasma concentrations of oxidised proteins in rats. Eur J Surg 1999; 165: 383-9.
37. Inagi R, Miyata T. Oxidative protein damage with carbohydrates and lipids in uremia: Carbonyl stress. Blood Purif 1999; 17: 95-8.
38. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
39. Popadiuk S, Korzon M, Renke J et al. Carbonyl groups content on the basis of protein peroxidation analysis with total antioxidant status in blood of children with cancers. Wiad Lek 1998; 51 (Suppl 4): 107-12.
40. Pignatelli B, Li CQ, Boffetta P et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001; 61: 778-84.
41. Yilmaz IA, Akcay T, Cakatay U et al. Relation between bladder cancer and protein oxidation. Int Urol Nephrol 2003; 35: 345-50.
42. Danielski M, Ikizler TA, McMonagle E et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003; 42: 286-94.
43. 2-isoprostanes and plasma antioxidant potential. Nephrol Dial Transplant 2001; 16: 1626-30.
44. Stenvinkel P, Holmberg I, Heimburger O et al. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 1998; 13: 2594-600.
45. Grant AJ, Jessup W, Dean RT. Accelerated endocytosis and incomplete catabolism of radical-damaged protein. Biochim Biophys Acta 1992; 1134: 203-9.
46. Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000; 97: 137-51.
47. Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358-63.
48. Witko-Sarsat V, Friedlander M, Nguyen KT et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32.
49. Mera K, Anraku M, Kitamura K et al. The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005; 334: 1322-8.
50. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997; 272: 20313-16.
51. Maldonado PA, Negrini LA, Kaizer RR et al. Oxidative status in patients, submitted to conization and radiation treatments for uterine cervix neoplasia. Clin Chim Acta 2005; 366: 174-8.
52. Izuhara Y, Miyata T, Saito K et al. Ultrapure dialysate decreases plasma pentosidine, a marker of 'carbonyl stress'. Am J Kidney Dis 2004; 43: 1024-9.
53. Ceriello A, Mercuri F, Quagliaro L et al. Detection of nitrotyrosine in the diabetic plasma: Evidence of oxidative stress. Diabetologia 2001; 44: 834-8.